"This new product candidate represents an extension of our platform and draws on our success to date in the development of our lead product candidate FavId® for the treatment of B-cell non-Hodgkin's lymphoma (NHL)," said John P. Longenecker, Ph.D., President and Chief Executive Officer of Favrille.
"This regulatory clearance by the FDA is an important milestone in the development of FAV-201 and we look forward to introducing it in the clinic."
FAV-201 is a recombinant, patient-specific, T-cell receptor-based immunotherapy designed to induce an active immune response against the unique protein found on the surface of T-cells that constitute a patient's lymphoma.
Read Favrille’s press release.
.jpg)
Comment Preview